$20m wheeze gives MediciNova breathing room for FDA and partnering
This article was originally published in Scrip
MediciNova entered into a common stock purchase agreement with Aspire Capital Fund that gives it access to $20 million over the next two years as the San Diego-based biopharma company prepares to tell the US FDA at a 22 October end-of-Phase II meeting why its acute asthma drug MN-221 (bedoradrine) should be tested in a Phase III clinical trial.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.